Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A Study to Evaluate ALN-2232 in Participants With Obesity

Eli Lilly · Phase 1/2 · Recruiting · Enrollment 156

NCT07463846

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Part A: ALN-2232n/rn/rn/rn/rn/r
Part A: Placebon/rn/rn/rn/rn/r
Part B: ALN-2232n/rn/rn/rn/rn/r
Part B: Placebon/rn/rn/rn/rn/r
Part C: ALN-2232n/rn/rn/rn/rn/r
Part C: Placebon/rn/rn/rn/rn/r
Part C: Tirzepatiden/rn/rn/rn/rn/r

A count stays a count. This page does not turn a count into a percent.